The Pharmacist's Perspective on Pharmacogenetics Implementation

被引：0

作者：

Weitendorf, Frederick ^{[1
,2
]}

Reynolds, Kristen K. ^{[2
,3
]}

机构：

[1] Robley Rex Vet Affairs Med Ctr, 800 Zorn Ave, Louisville, KY 40206 USA

[2] PGXL Labs, 201 East Jefferson St,Suite 309, Louisville, KY 40202 USA

[3] Univ Louisville, Sch Med, Dept Pathol & Lab Med, 627 South Preston St, Louisville, KY 40292 USA

来源：

CLINICS IN LABORATORY MEDICINE | 2016年 / 36卷 / 03期

关键词：

Pharmacogenetics; Pharmacokinetics; Pharmacodynamics; Drug-gene interaction; Personalized medicine; ADVERSE DRUG-REACTIONS; ANTICOAGULATION THERAPY; CODEINE THERAPY; METAANALYSIS; GUIDELINES; CYP2D6; GENOTYPES; EFFICACY; UPDATE; OPRM1;

D O I：

10.1016/j.cii.2016.05.009

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

The future for pharmacogenetics will continue to expand. Pharmacists can apply and incorporate drug knowledge in collaboration with other health providers using pharmacogenetics. Patients benefit with enhanced therapeutic outcomes that could lead to more streamlined drug approaches, fewer follow-up visits, cost savings, and shorter times to achieve therapeutic outcomes. As more drug-gene pathways are discovered and use of this knowledge increases, the potential for algorithm development for medication use will occur, resulting in better patient outcomes, higher standard of care, and reflect evidence-based medicine.

引用

页码：543 / +

页数：16

共 20 条

[1]

[Anonymous], 2008, Journal of American Pharmacists Association, V48, P341, DOI DOI 10.1331/JAPHA.2008.08514

[2]

[Anonymous], 2015, TABL PHARM BIOM DRUG

[3] Pharmacology and management of the vitamin K antagonists [J].

Ansell, Jack ;

Hirsh, Jack ;

Hylek, Elaine ;

Jacobson, Alan ;

Crowther, Mark ;

Palareti, Gualtiero .

CHEST, 2008, 133 (06) :160S-198S

[4] Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation [J].

Borgman, Mark P. ;

Pendleton, Robert C. ;

McMillin, Gwendolyn A. ;

Reynolds, Kristen K. ;

Vazquez, Sara ;

Freeman, Andrew ;

Wilson, Andrew ;

Valdes, Roland, Jr. ;

Linder, Mark W. .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) :561-569

[5] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Leeder, J. S. ;

Klein, T. E. ;

Caudle, K. E. ;

Haidar, C. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Sadhasivam, S. ;

Prows, C. A. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) :376-382

[6] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Klein, T. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) :321-326

[7]

FDA, 2012, DRUG SAF COMM DRUG S

[8] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [J].

Hicks, J. K. ;

Bishop, J. R. ;

Sangkuhl, K. ;

Mueller, D. J. ;

Ji, Y. ;

Leckband, S. G. ;

Leeder, J. S. ;

Graham, R. L. ;

Chiulli, D. L. ;

LLerena, A. ;

Skaar, T. C. ;

Scott, S. A. ;

Stingl, J. C. ;

Klein, T. E. ;

Caudle, K. E. ;

Gaedigk, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) :127-134

[9] Overview of Pharmacogenetics in Anticoagulation Therapy [J].

Hill, Charles E. ;

Duncan, Alexander .

CLINICS IN LABORATORY MEDICINE, 2008, 28 (04) :513-524

[10] Dynamic Pharmacogenetic Models in Anticoagulation Therapy [J].

Homme, Marjorie Bon ;

Reynolds, Kristen K. ;

Valdes, Roland, Jr. ;

Linder, Mark W. .

CLINICS IN LABORATORY MEDICINE, 2008, 28 (04) :539-552

← 1 2 →